Guardant Health, Inc. (GH) stock
GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$154.86+0.08 (+0.05%)
Close on Nov 12, 2026Market cap $20.78BP/E –Yield –
Guardant Health ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Guardant Health's ebitda for the twelve months ending Sep 30, 2026 was -$464.81M. For fiscal 2025 it was -$397.51M. The highest annual figure on record is -$40.15M in fiscal 2016.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$397.51M | – |
| FY2024 | Dec 31, 2024 | -$401.21M | – |
| FY2023 | Dec 31, 2023 | -$521.84M | – |
| FY2022 | Dec 31, 2022 | -$508.42M | – |
| FY2021 | Dec 31, 2021 | -$388.73M | – |
| FY2020 | Dec 31, 2020 | -$238.89M | – |
| FY2019 | Dec 31, 2019 | -$70.96M | – |
| FY2018 | Dec 31, 2018 | -$85.81M | – |
| FY2017 | Dec 31, 2017 | -$71.41M | – |
| FY2016 | Dec 31, 2016 | -$40.15M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$122.59M | – |
| Q2 FY2026 | Jun 30, 2026 | -$119.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$111.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$110.76M | – |
| Q3 FY2025 | Sep 30, 2025 | -$89.58M | – |
| Q2 FY2025 | Jun 30, 2025 | -$96.37M | – |
| Q1 FY2025 | Mar 31, 2025 | -$100.81M | – |
| Q4 FY2024 | Dec 31, 2024 | -$115.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$106.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$90.00M | – |
| Q1 FY2024 | Mar 31, 2024 | -$88.97M | – |
| Q4 FY2023 | Dec 31, 2023 | -$186.64M | – |
| Q3 FY2023 | Sep 30, 2023 | -$102.51M | – |
| Q2 FY2023 | Jun 30, 2023 | -$108.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$123.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$135.95M | – |
| Q3 FY2022 | Sep 30, 2022 | -$134.79M | – |
| Q2 FY2022 | Jun 30, 2022 | -$121.54M | – |
| Q1 FY2022 | Mar 31, 2022 | -$116.14M | – |
| Q4 FY2021 | Dec 31, 2021 | -$92.12M | – |
| Q3 FY2021 | Sep 30, 2021 | -$101.74M | – |
| Q2 FY2021 | Jun 30, 2021 | -$92.02M | – |
| Q1 FY2021 | Mar 31, 2021 | -$102.85M | – |
| Q4 FY2020 | Dec 31, 2020 | -$86.56M | – |
| Q3 FY2020 | Sep 30, 2020 | -$69.90M | – |
| Q2 FY2020 | Jun 30, 2020 | -$50.82M | – |
| Q1 FY2020 | Mar 31, 2020 | -$31.61M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.51M | – |
| Q3 FY2019 | Sep 30, 2019 | -$14.53M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.61M | – |
| Q1 FY2019 | Mar 31, 2019 | -$21.31M | – |
| Q4 FY2018 | Dec 31, 2018 | -$25.22M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.20M | – |
| Q2 FY2018 | Jun 30, 2018 | -$21.13M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.25M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.23M | – |
See a number that looks wrong?